BioSpace News Archive

The International Myeloma Foundation launched a multiyear, multidisciplinary initiative called “M-Power Charlotte,” designed to empower people to change the course of myeloma by removing barriers to early diagnosis and treatment in the African-American community.

Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease, announced today that the company has initiated a Phase 2 study evaluating the efficacy of RBT-1 on acute kidney injury (AKI) prevention in subjects undergoing coronary artery bypass

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food & Drug Administration (FDA) has granted expanded access approval for the administration of Longeveron’s investigational cell therapy Lomecel-B to a child with Hypoplastic Left Heart Syndrome (HLHS).

Persephone Biosciences Inc., a privately held, data-driven microbiome-focused biotechnology company, today announced the initiation of the VOICES clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of COVID-19 vaccination.

Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize the SARS-CoV-2 virus, including the E484K and N501Y mutations

Alafair Biosciences, Inc., a commercial-stage medical device company, announced the launch of VersaWrap®, a bioresorbable hydrogel implant that provides a gelatinous, non-constricting interface between tendons and/or peripheral nerves and surrounding tissues.

In a Series A round, Covid Apollo announces its investment in Rhinostics, an early-stage company that provides a novel solution of enabling comfortable sample collection, rapid accessioning, and automated cap removal that can be linked to high throughput Covid-19 assays to remove wasted time, headcount and costs from laboratory workflows.

Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announces that Chief Executive Officer Oliver Peoples, PhD. will present at Maxim Group’s 2021 Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced the complete 3-month bone biomarker data analysis from the ongoing Phase 2 clinical trial of EB613.